HCV core lipid binding domain monoclonal antibodies
The present invention relates to monoclonal antibodies for the detection of HCV antigen. More specifically, the invention describes antibodies against HCV core antigen lipid binding domain and immunoassay methods, kits and compositions for use in detecting HCV infection.
1. A monoclonal antibody that specifically binds with the lipid binding domain of HCV core antigen, wherein the monoclonal antibody comprises a heavy chain variable domain amino acid sequence of SEQ ID NO: 18 and a light chain variable domain amino acid sequence of SEQ ID NO: 310.
2. The monoclonal antibody of claim 1 , wherein said HCV core antigen is amino acid residues 134-171 of HCV (SEQ ID NO: 578).
3. An immunoassay reagent comprising the monoclonal antibody of claim 1 , wherein the monoclonal antibody comprises a detectable label.
4. The immunoassay reagent of claim 3 , wherein the monoclonal antibody is bound to a solid phase.
5. The immunoassay reagent of claim 3 , further comprising an additional antibody against an HCV antigen.
6. The immunoassay reagent of claim 5 , wherein the additional antibody is an additional anti-HCV core antibody.
7. An immunoassay for the detection of HCV in a test sample, the immunoassay comprising:
(i) contacting a test sample suspected of containing HCV with a first antibody directed against HCV core antigen to form a first complex between the first antibody and HCV core antigen located within said test sample;
(ii) contacting the complex formed in step (i) with the antibody of claim 1 , which is detectably labeled, to form a second complex with the antibody and antigen in the first complex formed in step (i), and
(iii) detecting the label of the second complex formed in step (ii).
8. The immunoassay of claim 7 , wherein the first antibody is directed to the DNA binding domain of HCV core antigen.
9. The immunoassay of claim 7 , wherein the antibody of step (ii) comprises a fluorescent label.
10. The immunoassay of claim 9 , wherein the fluorescent label is acridinium.
11. The immunoassay of claim 7 , wherein the first antibody of step (i) is bound to a solid phase.
12. The immunoassay of claim 7 , wherein the first antibody of step (i) is a monoclonal antibody that is specifically immunoreactive with the lipid binding domain of HCV core antigen and that is distinct from the antibody of step (ii).
13. The immunoassay of claim 7 , wherein the first antibody of step (i) is a monoclonal antibody that is specifically immunoreactive with the same lipid binding domain of HCV core antigen as the antibody of step (ii).
14. The immunoassay of claim 7 , wherein the test sample is obtained from a patient and the method further comprises diagnosing, prognosticating, or assessing the efficacy of a therapeutic/prophylactic treatment of the patient.
15. The immunoassay method of claim 14 , wherein the method is adapted for use in an automated system or a semi-automated system.
16. A kit comprising the immunodiagnostic reagent of claim 1 and instructions for the use of the immunodiagnostic reagent in an immunoassay for detection of HCV in a test sample.
17. The immunoassay reagent of claim 4 , further comprising an additional antibody against an HCV antigen.
18. The immunoassay of claim 14 , which further comprises assessing the efficacy of a therapeutic/prophylactic treatment of the patient, and optionally further comprises modifying the therapeutic/prophylactic treatment of the patient as needed to improve efficacy.